
Risankizumab safe, effective at 52 weeks for psoriatic arthritis
Risankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently published in Rheumatology. Andrew Östör, M.D., …
Risankizumab safe, effective at 52 weeks for psoriatic arthritis Read More